Literature DB >> 26155504

Comparative Analysis of Clinical Factors Associated with Ocular Surface Squamous Neoplasia in HIV Infected and Non HIV Patients.

Ruchi C Kabra1, Isha A Khaitan2.   

Abstract

INTRODUCTION: Ocular surface squamous neoplasia (OSSN) refers to a spectrum of conjunctival and corneal epithelial disease ranging from dysplasia to invasive carcinoma. HIV infection is an important risk factor postulated for the development of disease. AIM: To compare and to find out any statistically significant difference in patient demographics, clinical features and pathological findings in HIV infected and non-HIV infected histologically proven cases of ocular surface squamous neoplasia (OSSN).
MATERIALS AND METHODS: In the present retrospective case study, data from indoor case records and ocular pathology records of histologically proven cases of OSSN was obtained. The data was then tabulated under various clinicopathological headings in HIV affected and non HIV affected groups. A chi-square test was applied to compare data of two groups and look for any significant difference between two groups. A p-value less than 0.05 was considered significant.
RESULTS: Amongst the total of 48 patients, 11 were HIV positive and 37 were HIV negative. Age of the patients ranged from 14-66 years in HIV and 22-66 years in non HIV group with a preponderance of younger age patients in HIV positive group. 54.5% patients with lesion having base more than 5mm were observed at the time of presentation in HIV positive population as compared to 21.6% in non HIV cases. Feeder vessels were seen in all HIV patients and a significantly greater degree of fornicial involvement was noted in comparison with non-HIV group. Histopathological analysis showed 63.63% of cases to be of invasive carcinoma amongst the HIV positive group and 54.05% of invasive carcinoma in non HIV group.
CONCLUSION: Younger age and aggressive looking tumour at presentation should caution ophthalmologist to look for an undiagnosed HIV infection in OSSN patients.

Entities:  

Keywords:  Conjunctival squamous neoplasia; HIV and ocular neoplasia

Year:  2015        PMID: 26155504      PMCID: PMC4484096          DOI: 10.7860/JCDR/2015/13236.5932

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  21 in total

Review 1.  Acquired immunodeficiency syndrome-associated cancers in Sub-Saharan Africa.

Authors:  J O Thomas
Journal:  Semin Oncol       Date:  2001-04       Impact factor: 4.929

2.  Clinical factors associated with malignancy and HIV status in patients with ocular surface squamous neoplasia at Kilimanjaro Christian Medical Centre, Tanzania.

Authors:  Irma Illyes Makupa; Britta Swai; William Uforo Makupa; Valerie A White; Susan Lewallen
Journal:  Br J Ophthalmol       Date:  2011-11-10       Impact factor: 4.638

3.  Demographics, etiology, and behavior of conjunctival squamous cell carcinoma in the 21st century.

Authors:  Zeynel A Karcioglu; Michael D Wagoner
Journal:  Ophthalmology       Date:  2009-11       Impact factor: 12.079

4.  Predictors of ocular surface squamous neoplasia recurrence after excisional surgery.

Authors:  Anat Galor; Carol L Karp; Patrick Oellers; Andrew A Kao; Amany Abdelaziz; William Feuer; Sander R Dubovy
Journal:  Ophthalmology       Date:  2012-06-14       Impact factor: 12.079

Review 5.  Ocular surface squamous neoplasia.

Authors:  G A Lee; L W Hirst
Journal:  Surv Ophthalmol       Date:  1995 May-Jun       Impact factor: 6.048

6.  Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience.

Authors:  J Frucht-Pery; J Sugar; J Baum; J E Sutphin; J Pe'er; H Savir; E J Holland; D M Meisler; J A Foster; R Folberg; Y Rozenman
Journal:  Ophthalmology       Date:  1997-12       Impact factor: 12.079

7.  Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia.

Authors:  Amber Sturges; Amir L Butt; James E Lai; James Chodosh
Journal:  Ophthalmology       Date:  2008-02-21       Impact factor: 12.079

8.  Plaque brachytherapy for the management of ocular surface malignancies with corneoscleral invasion.

Authors:  Natalie Walsh-Conway; R Max Conway
Journal:  Clin Exp Ophthalmol       Date:  2009-08       Impact factor: 4.207

Review 9.  Tumors of the conjunctiva and cornea.

Authors:  Carol L Shields; Jerry A Shields
Journal:  Surv Ophthalmol       Date:  2004 Jan-Feb       Impact factor: 6.048

10.  Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification.

Authors:  Sanket U Shah; Swathi Kaliki; H Jane Kim; Sara E Lally; Jerry A Shields; Carol L Shields
Journal:  Arch Ophthalmol       Date:  2012-02
View more
  6 in total

Review 1.  Human Papilloma Virus Vaccination and Incidence of Ocular Surface Squamous Neoplasia.

Authors:  Joy N Carroll; Zachary I Willis; Annabelle de St Maurice; Sahar Kohanim
Journal:  Int Ophthalmol Clin       Date:  2017

2.  Update on the Management of Ocular Surface Squamous Neoplasia.

Authors:  Umangi Patel; Carol L Karp; Sander R Dubovy
Journal:  Curr Ophthalmol Rep       Date:  2021-02-20

3.  Ocular Surface Squamous Neoplasia (OSSN): A Retrospective Study.

Authors:  Padma Prabha Dandala; Padma Malladi
Journal:  J Clin Diagn Res       Date:  2015-11-01

4.  A prospective study of the incidence, associations and outcomes of ocular surface squamous neoplasia in the United Kingdom.

Authors:  Christine A Kiire; Rosalind M K Stewart; Sathish Srinivasan; Heinrich Heimann; Stephen B Kaye; Baljean Dhillon
Journal:  Eye (Lond)       Date:  2018-12-28       Impact factor: 3.775

Review 5.  Ocular surface squamous neoplasia in HIV-infected patients: current perspectives.

Authors:  Shweta Gupta Rathi; Anasua Ganguly Kapoor; Swathi Kaliki
Journal:  HIV AIDS (Auckl)       Date:  2018-03-14

Review 6.  Clinical Management of Ocular Surface Squamous Neoplasia: A Review of the Current Evidence.

Authors:  Maria Vittoria Cicinelli; Alessandro Marchese; Francesco Bandello; Giulio Modorati
Journal:  Ophthalmol Ther       Date:  2018-07-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.